Cholestech begins US delivery of liver enzyme test:
This article was originally published in Clinica
Hayward, California-based diagnostics developer Cholestech has begun shipping in the US its Aspartate Aminotransferase (AST) test for assessing damage to the liver due to drugs or certain diseases. The assay, the only CLIA-waivered one of its kind, runs on Cholestech's LDX system in conjunction with its other liver enzyme test, Alanine Aminotransferase (ALT). Nearly 200 million ALT and AST tests are ordered in the US each year, says Cholestech.
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.